Literature DB >> 26191235

Clinical significance of up-regulated ID1 expression in Chinese de novo acute myeloid leukemia.

Jing-Dong Zhou1, Lei Yang1, Xiao-Wen Zhu1, Xiang-Mei Wen2, Jing Yang1, Hong Guo2, Qin Chen2, Dong-Ming Yao2, Ji-Chun Ma2, Jiang Lin2, Jun Qian1.   

Abstract

To investigate the clinical significance of ID1 expression in Chinese de novo AML patients. Real-time quantitative PCR was carried out to detect the status of ID1 expression in 102 de novo AML patients and 28 controls. ID1 transcript level was significantly increased in AML compared to normal controls (p=0.029). The age in the patients with high ID1 expression is significantly older than in those with low ID1 expression (p=0.044). ID1 overexpression occurred with the highest frequency in the patients with poor karyotype (7/7, 100%), lower frequency in the patients with intermediate karyotype (28/60, 47%), and the lowest frequency in the patients with favorable karyotype (12/31, 39%). Both whole AML and non-M3 patients with high ID1 expression had significantly lower rate of complete remission than those with low ID1 expression (p=0.007 and 0.038). ID1 high-expressed patients showed significantly shorter overall survival (OS) than ID1 low-expressed patients in both whole AML and non-M3 according to Kaplan-Meier analysis (p=0.007 and 0.040). However, multivariate analysis indicated that ID1 overexpression was not an independent risk factor in both whole AML and non-M3 patients. However, the adverse impact of ID1 overexpression on outcome was revealed by both Kaplan-Meier analysis and multivariate analysis in the non-M3 patients less than 60 years old. Our study reveals that ID1 overexpression may be associated with higher risk karyotype classification and act as an independent risk factor in young non-M3 patients.

Entities:  

Keywords:  ID1; acute myeloid leukemia; expression; prognosis

Mesh:

Substances:

Year:  2015        PMID: 26191235      PMCID: PMC4503106     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  39 in total

1.  MicroRNA-381 represses ID1 and is deregulated in lung adenocarcinoma.

Authors:  Sacha I Rothschild; Mario P Tschan; Rolf Jaggi; Martin F Fey; Mathias Gugger; Oliver Gautschi
Journal:  J Thorac Oncol       Date:  2012-07       Impact factor: 15.609

2.  MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma.

Authors:  S I Rothschild; M P Tschan; E A Federzoni; R Jaggi; M F Fey; M Gugger; O Gautschi
Journal:  Oncogene       Date:  2012-01-16       Impact factor: 9.867

3.  Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance.

Authors:  Mariano Ponz-Sarvisé; Paul A Nguewa; María J Pajares; Jackeline Agorreta; María D Lozano; Miriam Redrado; Ruben Pio; Carmen Behrens; Ignacio I Wistuba; Carlos E García-Franco; Jesús García-Foncillas; Luis M Montuenga; Alfonso Calvo; Ignacio Gil-Bazo
Journal:  Clin Cancer Res       Date:  2011-05-03       Impact factor: 12.531

4.  Prognostic relevance of Id-1 expression in patients with resectable esophageal squamous cell carcinoma.

Authors:  Kong-Jia Luo; Jing Wen; Xuan Xie; Jian-Hua Fu; Rong-Zhen Luo; Qiu-Liang Wu; Yi Hu
Journal:  Ann Thorac Surg       Date:  2012-04-04       Impact factor: 4.330

5.  Expression and prognostic values of Id-1 and Id-3 in gastric adenocarcinoma.

Authors:  Hai-Yan Yang; Hao-Ling Liu; Gai-Yun Liu; Hong Zhu; Qing-Wen Meng; Lian-Dong Qu; Lian-Xin Liu; Hong-Chi Jiang
Journal:  J Surg Res       Date:  2009-09-09       Impact factor: 2.192

6.  ID1 expression associates with other molecular markers and is not an independent prognostic factor in cytogenetically normal acute myeloid leukaemia.

Authors:  Frederik Damm; Katharina Wagner; Kerstin Görlich; Michael Morgan; Felicitas Thol; Haiyang Yun; Ruud Delwel; Peter J M Valk; Bob Löwenberg; Michael Heuser; Arnold Ganser; Jürgen Krauter
Journal:  Br J Haematol       Date:  2012-05-09       Impact factor: 6.998

7.  U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Jun Qian; Dong-ming Yao; Jiang Lin; Wei Qian; Cui-zhu Wang; Hai-yan Chai; Jing Yang; Yun Li; Zhao-qun Deng; Ji-chun Ma; Xing-xing Chen
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

8.  IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Jiang Lin; Dong-ming Yao; Jun Qian; Qin Chen; Wei Qian; Yun Li; Jing Yang; Cui-zhu Wang; Hai-yan Chai; Zhen Qian; Gao-fei Xiao; Wen-rong Xu
Journal:  Ann Hematol       Date:  2011-10-14       Impact factor: 4.030

9.  Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Jiang Lin; Dong-ming Yao; Jun Qian; Qin Chen; Wei Qian; Yun Li; Jing Yang; Cui-zhu Wang; Hai-yan Chai; Zhen Qian; Gao-fei Xiao; Wen-rong Xu
Journal:  PLoS One       Date:  2011-10-31       Impact factor: 3.240

10.  Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma.

Authors:  O Straume; L A Akslen
Journal:  Br J Cancer       Date:  2005-10-17       Impact factor: 7.640

View more
  8 in total

1.  Epigenetic dysregulation of NKD2 is a valuable predictor assessing treatment outcome in acute myeloid leukemia.

Authors:  Xi-Xi Li; Jing-Dong Zhou; Ting-Juan Zhang; Lei Yang; Xiang-Mei Wen; Ji-Chun Ma; Jing Yang; Zhi-Hui Zhang; Jiang Lin; Jun Qian
Journal:  J Cancer       Date:  2017-02-11       Impact factor: 4.207

2.  Establishment and molecular characterization of decitabine-resistant K562 cells.

Authors:  Xiang-Mei Wen; Ting-Juan Zhang; Ji-Chun Ma; Jing-Dong Zhou; Zi-Jun Xu; Xiao-Wen Zhu; Qian Yuan; Run-Bi Ji; Qin Chen; Zhao-Qun Deng; Jiang Lin; Jun Qian
Journal:  J Cell Mol Med       Date:  2019-02-22       Impact factor: 5.310

3.  NPM1A in Plasma is a Potential Prognostic Biomarker in Acute Myeloid Leukemia.

Authors:  Chengming Sun; Yujie Gao; Liping Yang; Huiyuan Shao; Jie Li; Xuejun Gao; Li Ma; Mingming Lin; Jingrui Sui
Journal:  Open Life Sci       Date:  2018-08-21       Impact factor: 0.938

Review 4.  Inhibitor of DNA binding proteins revealed as orchestrators of steady state, stress and malignant hematopoiesis.

Authors:  Shweta Singh; Tanmoy Sarkar; Brad Jakubison; Stephen Gadomski; Andrew Spradlin; Kristbjorn O Gudmundsson; Jonathan R Keller
Journal:  Front Immunol       Date:  2022-08-05       Impact factor: 8.786

5.  The Down-Regulation of Circ_0059707 in Acute Myeloid Leukemia Promotes Cell Growth and Inhibits Apoptosis by Regulating miR-1287-5p.

Authors:  Jichun Ma; Xiangmei Wen; Zijun Xu; Peihui Xia; Ye Jin; Jiang Lin; Jun Qian
Journal:  Curr Oncol       Date:  2022-09-18       Impact factor: 3.109

6.  High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions.

Authors:  Lin Fu; Huaping Fu; Qingyun Wu; Yifan Pang; Keman Xu; Lei Zhou; Jianlin Qiao; Xiaoyan Ke; Kailin Xu; Jinlong Shi
Journal:  J Transl Med       Date:  2017-07-19       Impact factor: 5.531

7.  High bone marrow ID2 expression predicts poor chemotherapy response and prognosis in acute myeloid leukemia.

Authors:  Jing-Dong Zhou; Ji-Chun Ma; Ting-Juan Zhang; Xi-Xi Li; Wei Zhang; De-Hong Wu; Xiang-Mei Wen; Zi-Jun Xu; Jiang Lin; Jun Qian
Journal:  Oncotarget       Date:  2017-09-01

Review 8.  Inhibitor of Differentiation 1 (Id1) in Cancer and Cancer Therapy.

Authors:  Zhengxiao Zhao; Zhiyuan Bo; Weiyi Gong; Yong Guo
Journal:  Int J Med Sci       Date:  2020-04-06       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.